tirzepatide bipolar not linked to increased risk for depression tirzepatide bipolar FDA Approves Tirzepatide

Insurance coverage is inconsistent

37 Similarly, in a retrospective cohort study of 3435 people with type 2 diabetes exposed to tirzepatide for 180 days and over compared with a matched unexposed cohort, tirzepatide was associated with an increased risk of new-onset proliferative diabetic retinopathy primarily in those with pre-existing nonproliferative diabetic retinopathy

#HealthcareAdvertising #CTV #Pharma #Programmatic To view or add a comment, sign in Excited to share that my first first-author paper was published in JMCP last month

Leverage Advanced Tools: Utilize Katalys advanced marketing tools to optimize offers and track performance metrics

Optimizing IGF-I for skeletal muscle therapeutics